Company profile
Xilio Therapeutics, Inc.
NASDAQ: XLO · Healthcare · Biotechnology
#454 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
38DFH 44DQ 27GM —SS 44
v0.1 · 55/100 weight · provisional
↑ revenue growth (YoY), return on assets · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$64.1M
Rev growth YoY (TTM)
+327.3%
Net income (FY)
-$35.0M
Employees
76
as of 2026-08-19
Market cap
$62.5M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$43.8M$43.8M2025
Net income-$35.0M-$35.0M2025
Operating income-$42.0M-$42.0M2025
Total assets$154.7M$154.7M2025
Liabilities$119.4M$119.4M2025
Equity$35.3M$35.3M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Xilio Therapeutics, Inc.’s revenue?
Xilio Therapeutics, Inc. booked $43.8M in FY2025 revenue, growing 590% year over year — faster than 95% of Healthcare companies we track, at a -80.1% net margin.
Peers · Healthcare
New York Health Care, Inc.——SANUWAVE Health Inc.74BHOOKIPA Pharma Inc.——MedAvail Holdings, Inc.——Wave Life Sciences Ltd.63CRubicon Organics Inc.63CNeighbors
Middlesex →Key facts
CEORene Russo
SectorHealthcare
IndustryBiotechnology
HeadquartersWaltham, MA
ExchangeNASDAQ: XLO
Employees76
IPO date2021-10-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.